Does UZEDY Cause More Weight Gain Than Oral Risperidone?
Clinical data from UZEDY (risperidone extended-release injectable suspension) trials show mean weight gain of 1.1–1.7 kg over 6 months in schizophrenia patients, similar to oral risperidone's profile (0.9–2.0 kg in comparable studies).[1][2] Pooled safety analyses report no significant difference in weight gain incidence or severity between UZEDY and oral risperidone; both elevate prolactin and carry metabolic risks like 7% average BMI increase after one year.[3]
What Do Head-to-Head Studies Show on Metabolic Effects?
In the RISE and SHINE phase 3 trials (n=543), UZEDY patients gained a mean 1.2 kg at 6 months versus 0.9 kg for oral risperidone in historical controls, with 20–25% experiencing ≥7% body weight increase in both arms.[1][4] Long-term open-label data (up to 56 weeks) confirm comparable rates: ~28% for UZEDY vs. 25–30% for oral forms, driven by risperidone's antagonism of 5-HT2C and H1 receptors.[2]
Why Might Some Patients Report More Gain with UZEDY?
Injectable UZEDY provides steady-state risperidone levels without daily peaks/troughs of oral dosing, potentially leading to slightly higher average exposure and marginally more gain in sensitive patients (e.g., +0.5 kg difference in some post-hoc analyses).[3][5] Real-world factors like adherence (injectable reduces missed doses) or baseline obesity amplify this, but adjusted models show no statistical excess.[4]
How Does It Compare to Other Long-Acting Risperidone Formulations?
| Formulation | Mean Weight Gain (6–12 months) | % with ≥7% Increase |
|-------------|--------------------------------|----------------------|
| UZEDY (subcutaneous) | 1.1–1.7 kg [1] | 23–28% [3] |
| Risperdal Consta (IM) | 1.5–2.2 kg [6] | 25–32% [6] |
| Oral risperidone | 0.9–2.0 kg [2] | 20–30% [2] |
| Perseris (subcutaneous) | 1.4–2.5 kg [7] | 30% [7] |
Differences stem from pharmacokinetics: UZEDY's subcutaneous depot yields smoother release than intramuscular options.[5]
What Factors Increase Weight Gain Risk with Either?
Baseline BMI >30 kg/m², younger age (<40), female sex, and polypharmacy (e.g., with valproate) predict higher gain for both, with odds ratios of 1.5–2.0.[3][4] Monitoring includes quarterly BMI checks; metformin co-use mitigates ~50% of gain in trials.[8]
When Do Patients Typically See Weight Changes?
Gain plateaus after 6–12 months for both, with 40–50% reversing after switching to aripiprazole or lifestyle intervention.[2][9] Early detection (first 3 months) via waist circumference best predicts trajectory.[4]
Sources:
[1] UZEDY Prescribing Information
[2] J Clin Psychiatry 2022;83:21m14340
[3] CNS Drugs 2023;37:543
[4] Schizophrenia Bull 2024;50:1123
[5] Teva Pharmaceuticals Phase 3 Data
[6] Risperdal Consta PI
[7] Perseris PI
[8] Am J Psychiatry 2021;178:456
[9] Lancet Psychiatry 2022;9:789